On the choice of doses for phase III clinical trials
Crossref DOI link: https://doi.org/10.1002/sim.5632
Published Online: 2012-09-30
Published Print: 2013-05-10
Update policy: https://doi.org/10.1002/crossmark_policy
Lisovskaja, Vera
Burman, CarlāFredrik
Version of Record valid from 2012-09-30
Text and Data Mining valid from 2015-09-01